| Achaogen is a biopharmaceutical company engaged in discovering, developing, and commercializing antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. Co. develops plazomicin for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Co. also develops antibacterial candidate, C-Scape, an orally-administered combination of ceftibuten and clavulanate for oral treatment for patients with cUTI, and acute pyelonephritis, caused by expanded spectrum beta-lactamases-producing Enterobacteriaceae. We show 21 historical shares outstanding datapoints in our AKAO shares outstanding history coverage, used to compute AKAO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AKAO market cap history over the course of time is important for investors
interested in comparing AKAO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AKAO versus a peer is one thing; comparing
AKAO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AKAO can fluctuate over the course of history.
With this page we aim to empower investors researching AKAO by allowing them to research the AKAO market cap history.